Drug Profile
Gabapentin extended release - Alvogen
Alternative Names: DM-1796; DM-5689; Gabapentin ER; Gabapentin GR; Gralise; Sefelsa; SeradaLatest Information Update: 05 Nov 2021
Price :
$50
*
At a glance
- Originator Depomed; Elan Corporation
- Developer Assertio Therapeutics
- Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Gabapentinoids; Small molecules
- Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postherpetic neuralgia
- Discontinued Diabetic neuropathies; Hot flashes
Most Recent Events
- 10 Jan 2020 Alvogen acquires Gabapentin extended release from Assertio Therapeutics
- 12 Dec 2019 Alvogen is expected to complete acquisition of gabapentin extended release in early January 2020
- 12 Dec 2019 Alvogen enters into a purchase agreement with Assertio Therapeutics for Gabapentin extended release